Bacil Pharma Limited Appoints New Company Secretary Following Recent Resignation
Bacil Pharma Limited announced the proposed appointment of Mr. Dikshant Singh Panwar as Company Secretary, replacing Bhavana Phoolchand Tak who resigned effective December 1, 2025. The new appointee holds membership number ACS42741 and has extensive compliance experience. The appointment requires board confirmation and follows SEBI regulatory requirements.

*this image is generated using AI for illustrative purposes only.
Bacil Pharma Limited has announced the proposed appointment of a new Company Secretary following the recent resignation of its previous officer. The company disclosed that Mr. Dikshant Singh Panwar has been proposed for the position of Company Secretary, with confirmation expected in the next board meeting.
Recent Personnel Changes
The appointment comes after Bhavana Phoolchand Tak, who served as the Company Secretary and Compliance Officer, tendered her resignation effective December 1, 2025, to pursue an alternate career opportunity outside the organization.
| Personnel Details: | Information |
|---|---|
| Outgoing Officer: | Bhavana Phoolchand Tak |
| Resignation Date: | December 1, 2025 |
| Proposed New Officer: | Mr. Dikshant Singh Panwar |
| Membership Number: | ACS42741 |
| Status: | Pending board confirmation |
New Appointment Details
According to the company's communication to BSE Limited dated December 19, 2025, Mr. Dikshant Singh Panwar, a Company Secretary with membership number ACS42741, has been proposed for the role. The company stated that he has extensive experience in compliance services and meets all criteria regarding independence, eligibility, and qualifications as per the Companies Act, 2013, and SEBI regulations.
Regulatory Compliance
Both the resignation and proposed appointment have been disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has assured stakeholders that the appointment process follows all regulatory requirements.
Financial Context
This leadership transition occurs as Bacil Pharma Limited maintains its operational focus. The company's recent financial position as of March 2025 shows significant growth across key metrics:
| Financial Metric: | Value (₹ crore) | YoY Change |
|---|---|---|
| Total Assets: | 25.60 | +1869.23% |
| Shareholder's Capital: | 25.40 | +2016.67% |
| Current Assets: | 2.90 | +2800.00% |
| Investments: | 21.40 | +3466.67% |
The substantial year-over-year increases across these financial metrics highlight the importance of maintaining strong corporate governance and compliance practices during the company's growth phase. The prompt identification and proposed appointment of a qualified replacement demonstrates the company's commitment to maintaining regulatory compliance standards.
Historical Stock Returns for Bacil Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +0.50% | -5.85% | +0.64% | -38.82% | +635.31% |



























